Drug Profile
Nendratareotide uzatansine - Tarveda Therapeutics
Alternative Names: BTP-227; PEN-221Latest Information Update: 06 Jan 2022
Price :
$50
*
At a glance
- Originator Tarveda Therapeutics
- Class Antineoplastics; Drug conjugates; Maytansinoids
- Mechanism of Action Apoptosis inhibitors; DNA synthesis inhibitors; Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Neuroendocrine tumours; Small cell lung cancer
Most Recent Events
- 07 Jun 2021 Efficacy and safety data from a Phase-I/II trial in advanced neuroendocrine tumor released by the Tarveda Therapeutics
- 25 Feb 2021 Tarveda Therapeutics completes a phase II trial for Neuroendocrine tumours and Small cell lung cancer (Late-stage disease, Second-line therapy or greater) in United Kingdom and USA (IV) (NCT02936323)
- 23 Feb 2021 PEN 221 is still in phase II trial for Neuroendocrine tumours and Small cell lung cancer (Late-stage disease, Second-line therapy or greater) in United Kingdom, USA (IV) (NCT02936323)